Ketim Therapeutics Pty Ltd

What Ketim Therapeutics Pty Ltd does

Ketim Therapeutics Pty Ltd (doing business as Ketim Technologies) is an Australian, Brisbane-based biotechnology company founded in 2024 that is developing what it claims to be the world's first protein blood-based objective clinical test for postpartum depression (PPD). The core product is a predictive blood assay built on a proprietary four-protein biomarker signature reported to deliver up to 94% sensitivity and specificity (AUC) when performed at 24 weeks gestation — before symptoms manifest — derived from screening over 5,400 candidate proteins against multimodal patient data. The assay is paired with an AI/ML-enabled analytical pipeline and a proprietary database integrating biomarker, clinical, and patient-reported data, intended to support biomarker discovery, drug discovery, and clinical-trial optimization for psychiatric conditions more broadly. The company has filed an international PCT patent application covering the biomarker technology (Feb 2026) and is generating validation data through strategic partnerships with Mater Research (Queensland Family Cohort), the Australian Genome Research Facility (proteomics via Olink platforms), the Thompson Institute at the University of the Sunshine Coast, and provisional access to the ORIGINS Birth Cohort Biobank. A Swedish dried-blood-spot partnership with Capitainer extends sample-collection flexibility for the test.

The company is pre-revenue and pre-commercialization: no pricing is publicly disclosed, the product is not yet approved by the FDA, TGA, or equivalent regulators, and the trials.ketim.com.au portal exists to enroll validation cohorts rather than to deliver paid services. Planned revenue streams include clinical laboratory testing services and potential kit sales for the blood-based diagnostic, biomarker database licensing to pharmaceutical companies, and biomarker-driven clinical trial optimization services. Planned customer segments are healthcare providers and pregnant women for the diagnostic test, and pharmaceutical companies for the database and trial-optimization offerings. As of late 2025 / early 2026 the company had closed an oversubscribed AUD $1.2 million pre-seed round at a $3.7 million post-money valuation, accumulated roughly AUD $1.275 million in combined equity and non-dilutive grant funding (including a AUD $75K Advance Queensland Ignite Spark Grant), and was pursuing competitive grants reportedly aggregating to AUD $4.5 million for biomarker validation and regulatory progression. Go-to-market is enterprise/clinical field-sales led: direct engagement with clinicians, partnerships with maternity hospitals for cohort and biobank access, participation in accelerator programs (BEDA MedTech Global Accelerator, AusBiotech IGP), and investor and life-sciences conference presence (RESI JPM 2026, AusMedTech 2025). The operating geography is anchored in Australia with explicit strategic interest in Singapore/Southeast Asia and the United States.

Name

Ketim Therapeutics Pty Ltd

Legal name

Ketim Therapeutics Pty Ltd

Website

https://ketim.com.au

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Ketim Therapeutics (Ketim Technologies) is a Brisbane, Australia-based biotechnology company developing the world's first protein blood-based predictive test for postpartum depression, paired with an AI/ML-enabled multimodal biomarker database for maternal mental-health diagnostics and pharmaceutical drug-discovery applications.

Ownership category

akta.pro rank

Product category

Maternal Mental Health Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)

Keywords

• Biomarker diagnostics
• Postpartum depression screening
• Precision psychiatry
• Blood-based biomarker testing
• Maternal mental health

Headquarters

HQ city

Brisbane

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Blood-Based Diagnostic Test Sales: The company is developing and plans to commercialize a protein blood-based diagnostic test for postpartum depression prediction, expected to generate revenue through clinical laboratory testing services and potentially kit sales.
2. Biomarker Database Licensing: Licensing of proprietary biomarker database to pharmaceutical companies for drug discovery and development purposes.
3. Clinical Trial Optimization Services: Providing biomarker-driven insights to pharmaceutical companies for clinical trial design and patient stratification.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Ketim Technologies is commercializing a proprietary protein blood-based diagnostic test that predicts postpartum depression risk at 24 weeks gestation using a four-protein biomarker signature with up to 94% sensitivity and specificity (AUC), before symptoms occur. The company is also building an AI/ML-enabled proprietary multimodal database that integrates biomarker, clinical, and health data to support biomarker discovery, drug discovery, and clinical trial optimization for perinatal mental health.

Product overview

Ketim Technologies is developing the world's first protein blood-based objective clinical test for postpartum depression (PPD) using a proprietary four-protein biomarker signature achieving up to 94% sensitivity and specificity. The core offering consists of a predictive blood test that can identify PPD risk at 24 weeks gestation, before symptoms manifest. This is supported by an AI-driven proprietary database that integrates multimodal patient data (molecular, clinical, and health information) to power biomarker discovery and drug discovery for mental health conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Postpartum Depression (PPD) Blood Test A novel protein blood-based objective clinical test that predicts postpartum depression (PPD) risk using a proprietary four-protein biomarker signature with up to 94% sensitivity and specificity (AUC), performed at 24 weeks gestation—months before symptoms occur. Intended for healthcare providers, obstetricians, and antenatal care clinics to enable early screening and personalized intervention for pregnant women.
• AI-Driven Proprietary Biomarker and Drug Discovery Database A proprietary biomarker and drug discovery database that integrates multimodal patient data including molecular, clinical, and health information, powered by advanced AI and machine learning. Designed to uncover novel biomarkers, accelerate drug development, and optimize clinical trial design for pharmaceutical and biotech partners in mental health (starting with PPD).

Quantifiable outcome

• 94% sensitivity and specificity (AUC) for PPD prediction at 24 weeks gestation
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Mater ResearchcoreStrategic or Co-development PartnerStrategic partnership leveraging the Queensland Family Cohort (QFC) study for predictive biomarker research for perinatal depression. The collaboration provides access to longitudinal datasets encompassing genetic, environmental, and health factors for biomarker discovery.
• Australian Genome Research Facility (AGRF) LtdcoreStrategic or Co-development PartnerOngoing collaboration advancing biomarker discovery and translational pipeline. AGRF provides proteomics expertise and genomic technologies supporting Ketim's biomarker validation work using Olink proteomics platforms.
• Thompson Institute at University of the Sunshine CoastcoreStrategic or Co-development PartnerResearch collaboration to evaluate the specificity of Ketim's postpartum depression biomarker signature through independent validation studies.
• The Kids Research Institute (ORIGINS Birth Cohort Biobank)coreStrategic or Co-development PartnerProvisional approval to access the ORIGINS Birth Cohort Biobank for independent validation of postpartum depression biomarker panel. Enables validation studies in an independent birth cohort.
• Brisbane Economic Development Agency MedTech Global AcceleratorminorChannel Partner/ Reseller/ DistributorSelected for Year 4 Cohort of BEDA's MedTech Global Accelerator Program supporting global expansion strategy and commercialization pathways.
• AusBiotech (Industry Growth Program)coreStrategic or Co-development PartnerAusBiotech-delivered Industry Growth Program (IGP) providing commercialization pathway support, funded by Department of Industry, Science and Resources. Successfully completed 2025 program.
• Brisbane Economic Development AgencyminorGTM or Marketing PartnerSupport through MedTech Accelerator cohort and participation in RESI JPM Week activities, strengthening Queensland's MedTech ecosystem presence.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Alto Neuroscience: Clinical-stage precision psychiatry company using biomarker-driven patient stratification to develop depression and other CNS therapeutics. Closest strategic peer, employing a similar biomarker-and-AI strategy to address heterogeneity in depression, although Alto focuses on stratification for drug development rather than a predictive diagnostic test.

Broad incumbents

• Quest Diagnostics: Major clinical laboratory services provider with broad women's health and mental health testing menus. Comparable as a potential distribution and commercial partner for the PPD test, given its nationwide clinical lab infrastructure and existing payer relationships.
• Labcorp (Laboratory Corporation of America): Large clinical laboratory network with extensive maternal and women's health diagnostics, including NIPT and hormone testing. Comparable as a potential commercial partner for distribution and reimbursement of a novel blood-based PPD diagnostic.
• Myriad Genetics: Established molecular diagnostics company with a portfolio of genetic and biomarker tests across women's health, oncology, and mental health. Comparable as a large diagnostic player that could enter or replicate the PPD biomarker space, and a potential acquirer or partner for Ketim's pipeline.
• Sage Therapeutics: Commercial-stage biopharmaceutical company with Zurzuvae, the first FDA-approved oral therapy specifically for postpartum depression. Operates in the same PPD indication and validates clinical and commercial demand for PPD-focused innovation, though Sage is a drug developer rather than a diagnostics company.

Emerging players

• Mindstrong (historical): Digital biomarker company that used smartphone behavioral data and AI to detect and monitor mental health conditions. Comparable as an early-stage precision psychiatry company applying objective, data-driven biomarkers to mental health, though Mindstrong focused on digital rather than molecular biomarkers.
• Mahmee: Digital maternal health platform providing postpartum support, screening, and care navigation. Comparable as a maternal mental health company addressing the same end population (pregnant and postpartum mothers), though it focuses on care delivery rather than biomarker-based diagnostics.
• Brii Biosciences: Clinical-stage biotechnology company developing treatments for CNS and infectious diseases, with a growing emphasis on biomarker-driven approaches in mental health. Comparable in applying biomarker/AI strategies to psychiatric drug development, though it is focused on therapeutics rather than diagnostics.

Others

• SomaLogic: Protein biomarker discovery platform using SomaScan technology for high-throughput proteomics. Functions as an enabler/platform for protein biomarker discovery analogous to Olink, supporting similar downstream diagnostic applications in multiple therapeutic areas.
• Olink (Thermo Fisher Scientific): Leading proteomics platform provider (now part of Thermo Fisher) whose Olink technology Ketim uses for biomarker discovery. Comparable as a proteomics platform enabler, though Olink is a tools/technology provider rather than a downstream diagnostics developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ketim-technologies
• Xx.com/Ketim_Aus

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ketim Therapeutics Pty Ltd